News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Moberg Derma Obtains Approval For Seborrhoeic Eczema Product And Receives Iso 13485 Certification


4/13/2010 3:11:51 PM

Moberg Derma AB today announced that CE mark has been granted for its topical product for the management and relief of common scalp conditions associated with scaly and itchy skin, e.g. seborrhoeic eczema and dandruff. The CE mark provides authorization to market and sell the medical device product in the EU/EEA. The company also announced that it received ISO 13485 certification.

”We are now able to offer a new steroid-free treatment alternative in an indication area dominated by older products. The CE mark is a key milestone for the company and we look forward to making the product available to patients in collaboration with partners and distributors. The ISO 13485 certification is an important quality stamp of our operations”, says Moberg Derma's President and CEO, Peter Wolpert.

About the product and seborrhoeic dermatitis

The product is a prescription free topical solution indicated for the management of common scalp conditions such as seborrhoeic eczema and dandruff. Efficacy and safety have been demonstrated in several clinical studies including more than 300 patients. The product reduces itching and scaling and has a softening and moisturizing effect on the scalp.

Approximately 5% of the population suffers from seborrhoeic eczema of the scalp and skin. There is currently no cure for seborrhoeic eczema, which means that treatment focuses on minimizing symptoms, particularly scaling, erythema and itching.

Contact Moberg Derma

Peter Wolpert, President and CEO

Telephone: +46 8 - 522 307 00

Mobile: +46 70 - 735 71 35

E-mail: peter.wolpert@mobergderma.se

About Moberg Derma

Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights. The company began operations at the Karolinska Institute in 2006. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES